Leukemic IL-17RB signaling regulates leukemic survival and chemoresistance.
Guo HZ, Niu LT, Qiang WT, Chen J, Wang J, Yang H, Zhang W, Zhu J, Yu SH.
Guo HZ, et al. Among authors: yang h.
FASEB J. 2019 Aug;33(8):9565-9576. doi: 10.1096/fj.201900099R. Epub 2019 May 28.
FASEB J. 2019.
PMID: 31136196
Thus, the inhibition of the IL-17B-IL-17RB axis may be a valid strategy to enhance sensitivity and therapeutic benefit of AML chemotherapy.-Guo, H.-Z., Niu, L.-T., Qiang, W.-T., Chen, J., Wang, J., Yang, H., Zhang, W., Zhu, J., Yu, S.-H. Leukemic IL-17 …
Thus, the inhibition of the IL-17B-IL-17RB axis may be a valid strategy to enhance sensitivity and therapeutic benefit of AML chemotherapy.- …